Results 291 to 298 of about 205,038 (298)

Effect of high‐intensity interval exercise on metformin pharmacokinetics in healthy men, assessed through a population pharmacokinetic model

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Metformin and exercise are first‐line therapies for prediabetes and type 2 diabetes. However, it is unclear whether the combination of metformin and exercise is synergistic or antagonistic. The aim of this study was to investigate the effect of exercise on metformin pharmacokinetics and help clarify the contradictory ...
Stefanos Nikolaidis, Ioannis Kosmidis, Stylianos Papadopoulos, Artemis Lioupi, Marita Gandanidou, Helen Gika, Aristides Dokoumetzidis, Georgios Theodoridis, Vassilis Mougios   +8 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

pH/Glucose Dual Responsive Metformin Release Hydrogel Dressings with Adhesion and Self-Healing via Dual-Dynamic Bonding for Athletic Diabetic Foot Wound Healing.

ACS Nano, 2022
In view of the lack of a specific drug-sustained release system that is responsive to chronic wounds of the type II diabetic foot, and the demands for frequent movement at the foot wound, pH/glucose dual-responsive metformin-released adhesion-enhanced ...
Yongping Liang, Meng Li, Yutong Yang, Lipeng Qiao, Huiru Xu, Baolin Guo   +5 more
semanticscholar   +1 more source

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

The Lancet, 1998
R. Turner, R. Holman, I. Stratton, C. Cull, D. Matthews, S. Manley, V. Frighi, D. Wright, A. Neil, E. Kohner, H. Mcelroy, C. Fox, D. R. Hadden, Grp Ukpds.   +13 more
semanticscholar   +1 more source

Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug

Nature Network Boston, 2017
Hao Wu, E. Esteve, V. Tremaroli, M. Khan, R. Caesar, L. Mannerås-Holm, M. Ståhlman, Lisa M. Olsson, M. Serino, Mercè Planas-Fèlix, G. Xifra, J. Mercader, D. Torrents, R. Burcelin, W. Ricart, Rosie Perkins, J. Fernández-Real, F. Bäckhed   +17 more
semanticscholar   +1 more source

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

Nature Reviews Endocrinology, 2019
M. Foretz, B. Guigas, B. Viollet
semanticscholar   +1 more source

Metformin

Reactions weekly, 2019

semanticscholar   +1 more source

Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss

Nature Metabolism, 2019
Emily A. Day, R. Ford, Brennan K Smith, P. Mohammadi-Shemirani, Marisa R. Morrow, Robert M Gutgesell, R. Lu, A. Raphenya, M. Kabiri, A. McArthur, Natalia McInnes, S. Hess, G. Paré, H. Gerstein, G. Steinberg   +14 more
semanticscholar   +1 more source